Skip to content
My WebMD Sign In, Sign Up
Trastuzumab for Recurrent ER Pos patients
avatar
montrelblundell posted:
Some recent studies indicate that ER pos, Her2 neg patients with recurrent breast cancer may want to have their breast cancer mets retested for Her2. Many circulating breast cancer cells are turning out to be Her2 positive, making such patients eligible for trastuzumab and other solid her2 targeting therapies. Articles that talk about this: "Her2 and Breast Cancer Stem Cells: More than meets the Eye" in Cancer Research. And "HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer" in the NEJM. And "More Breast Cancer Patients Should Take Herceptin, Studies Hint" in Drug Discovery and Development.
Was this Helpful?
2 of 2 found this helpful
Reply


Helpful Tips

How to more easily read discussions
Exchanges provide a more dynamic way to keep up with ongoing discussions. But If you're finding how discussions and responses are ... More
Was this Helpful?
27 of 46 found this helpful

Related News

There was an error with this newsfeed

Related Drug Reviews

  • Drug Name User Reviews

Report Problems With Your Medications to the FDA

FDAYou are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

For more information, visit the Duke Health Breast Cancer Center